Fiscal Year 1990

Initial Public Offering

Fiscal Year 1991

Initial Launch of Pharmaceutical Products

Established Dermatological Sales Force

Fiscal Year 1992

Acquired ESOTERICA® from SmithKline Beecham

Fiscal Year 1993

Introduced DYNACIN®

Fiscal Year 1994

No Data Available

Fiscal Year 1995

Relocated to Phoenix, AZ

Fiscal Year 1996

Launched TRIAZ®

1 for 14 Reverse Stock Split

Fiscal Year 1997

Two 3 for 2 Stock Splits (August and March)

Completed Public Offering Raising More Than $95 Million

Introduced Dye-Free DYNACIN®

Acquired LIDEX® and SYNALAR® from Syntex

Fiscal Year 1998

Collaboration with Abbott Laboratories

Received Patent for TRIAZ®

Acquired GenDerm Corporation

Completed Public Offering Raising More Than $210 Million

Launched LUSTRA®

Fiscal Year 1999

Listed on NYSE

Acquired LOPROX® and TOPICORT® from Aventis (HMR)

Began Promotion to Podiatrists

3 for 2 Stock Split

Sold and Licensed Products to Bioglan

Acquired Ucyclyd Pharma

Established Stock Repurchase Program

Launched OVIDE®

Launched LUSTRA-AF®

Launched DYNACIN® 75 mg

Fiscal Year 2000

Received Patent on LUSTRA® Composition

Acquired VECTRIN® Product Line from Warner Chilcott

Chairman and CEO Selected to Serve on NYSE Advisory Committee

Launched LOPROX® Gel

Relocated to Scottsdale, AZ

Fiscal Year 2001

Launched PLEXION® and PLEXION® TS

Collaboration with Corixa

Announced PVAC™ Phase II Trial Preliminary Results

Licensed OMNICEF® from Abbott Laboratories for Dermatology and Podiatry in U.S.

Launched ALUSTRA®

Fiscal Year 2002

Completed Merger with Ascent Pediatrics

Began Promotion to Pediatricians

Launched PLEXION SCT®

Issued $350 Million Contingent Convertible Senior Notes Due 2032

Strategic Alliance with aaiPharma

Fiscal Year 2003

License and Development Agreement with Dow Pharmaceutical Sciences

Launched LOPROX TS®

Licensed Four Branded Products to Taro

Acquired Exclusive License to RESTYLANE® Family of Products

Launched LOPROX® Shampoo

Launched DYNACIN® Tablets

Fiscal Year 2004

Declared First Dividend

Launched TRIAZ® Pads

Completed Exchange Offer for Contingent Convertible Senior Notes Due 2033

Discontinued PVAC™ Development

2 for 1 Stock Split

Launched RESTYLANE®

Licensed ORAPRED® to BioMarin

Fiscal Year 2005

Licensed SubQ™ from Q-Med

Licensed LUSTRA® Family of Products to Taro

Launched PLEXION® Cleansing Cloths

Licensed Proprietary Peptide Technology from Ansata Therapeutics

Supermodel Frederique van der Wal Signed on as the New Face of RESTYLANE®

FDA Approved NDA for VANOS™

FDA Approved AMMONUL^®

Launched of Restylane Rewards(SM)

Announced Agreement to Merge with Inamed

Fiscal Year 2006

Filed Suit Against Upsher-Smith and Prasco

Board Unanimously Rejected Mentor Proposal

Requested That Inamed Recommend Rejection of Allergan Exchange Offer

Terminated Merger Agreement with Inamed; Received $90 Million Termination Fee

Calendar Year 2006

FDA Approved Broader Indication for VANOS®

Ipsen Granted Medicis Rights to Distribute and Promote Reloxin® to the Aesthetic Market

Two Patents Issued for LOPROX® Gel

FDA Approved SOLODYN® -- minocycline HCl, USP -- Extended Release Tablets

Launched Search for the "Hottest Mom in America"

Medicis and Dow Pharmaceutical Sciences announce FDA Approval of ZIANA® (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel

Calendar Year 2007

Launched ZIANA®

Launched PERLANE®

Launched TV Ad Campaign for RESTYLANE®

Announced Strategic Collaboration with Hyperion Therapeutics

Announced Share Repurchase Program up to $200 Million

BLA for RELOXIN^® in Aesthetics Submitted to FDA

Announced Strategic Collaboration with Revance Therapeutics

Calendar Year 2008

Increased Cash Dividend to $0.04 Per Share

BLA for RELOXIN® in Aesthetics Submitted to FDA by Ipsen

Announced Organizational Changes

BLA for RELOXIN® in Aesthetics Accepted by FDA

Announced Acquisition of LipoSonix